Danaher (NYSE:DHR) Reaches New 12-Month Low – Here’s What Happened

Danaher Co. (NYSE:DHR) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $203.00 and last traded at $203.42, with a volume of 7038666 shares. The stock had previously closed at $206.76.

Wall Street Analyst Weigh In

Several research firms recently commented on DHR. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Finally, KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Trading Down 1.6 %

The firm has a market capitalization of $146.92 billion, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business’s fifty day moving average is $232.72 and its 200 day moving average is $251.61.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the firm earned $2.09 earnings per share. Equities analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.53%. Danaher’s payout ratio is currently 20.45%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Danaher

Institutional investors and hedge funds have recently modified their holdings of the company. Heck Capital Advisors LLC bought a new stake in Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter valued at about $31,000. Golden State Wealth Management LLC acquired a new stake in Danaher during the fourth quarter worth approximately $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher during the fourth quarter worth approximately $31,000. Finally, Pineridge Advisors LLC boosted its stake in Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.